Mocertatug rezetecan

Phase 3

GSK

Mocertatug rezetecan is one of 47 therapeutic programs targeting Solid Tumor. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Solid TumorRecruiting

Ovarian NeoplasmsNot yet recruiting

Neoplasms, EndometrialRecruiting

Solid TumorPhase 1

Recruiting

Ovarian NeoplasmsPhase 3

Not yet recruiting

Neoplasms, EndometrialPhase 3

Recruiting

Competition

Competitive Landscape

171 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

8 2

Lenvima

Eisai

Phase 3

3 3

Lynparza

AstraZeneca

Phase 3

1 4

Bavencio

EMD Serono

Phase 3

1 5

Investigator's Choice of Chemotherapy

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3

1 6

MK-4280

Merck & Co.

Phase 3

1 7

MK-4280A

Merck & Co.

Phase 3

1 8

Mocertatug rezetecan

GSK

Phase 3

1 9

INCB161734

Incyte

Phase 3

1 10

Yervoy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 3Recruiting

Neoplasms, Endometrial

NCT07286331

Q4 2029

Phase 1Recruiting

Solid Tumor

NCT06431594

Q3 2030

Phase 3Recruiting

Ovarian Neoplasms

NCT07286266

Q4 2032

Phase 3Not yet recruiting

Ovarian Neoplasms

NCT07694427

Clinical

Trials by Indication[1]

Ovarian Neoplasms3 trials

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan With or Without Bevacizumab in Comparison to Active Observation With or Without Bevacizumab as Maintenance Treatment in Participants With Newly Diagnosed FIGO Stage III/IV Non-Homologous Recombination Deficient Ovarian Cancer

Not yet recruiting· GSK logo

GSK·Phase 3·NCT07694427·720 enrolled

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer

Recruiting· GSK logo

GSK·Phase 3·NCT07286266·450 enrolled

A Randomized, Open-Label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-Sensitive Ovarian Cancer

Not yet recruiting· GSK logo

GSK·Phase 3·NCT07684612·690 enrolled

Neoplasms, Endometrial1 trial

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy

Recruiting· GSK logo

GSK·Phase 3·NCT07286331·600 enrolled

Solid Tumor1 trial

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Subjects With Advanced Solid Tumors

Recruiting· GSK logo

GSK·Phase 1·NCT06431594·675 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Mocertatug rezetecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Mocertatug rezetecan. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: GSK

Mocertatug rezetecan

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q4 2029

Q3 2030

Q4 2032

Trials by Indication[1]

Ovarian Neoplasms3 trials

Neoplasms, Endometrial1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News